Diversified Trust Co Grows Stock Position in Medtronic PLC $MDT

Diversified Trust Co increased its stake in Medtronic PLC (NYSE:MDT) by 32.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,875 shares of the medical technology company’s stock after acquiring an additional 23,906 shares during the period. Diversified Trust Co’s holdings in Medtronic were worth $9,226,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Medtronic by 1.5% in the second quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after purchasing an additional 1,895,165 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Medtronic by 1.1% in the second quarter. Geode Capital Management LLC now owns 28,227,006 shares of the medical technology company’s stock worth $2,448,699,000 after purchasing an additional 310,684 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Medtronic by 2.9% in the second quarter. Bank of New York Mellon Corp now owns 21,275,850 shares of the medical technology company’s stock worth $1,854,616,000 after buying an additional 595,549 shares during the period. Invesco Ltd. raised its holdings in Medtronic by 3.9% during the 2nd quarter. Invesco Ltd. now owns 17,647,149 shares of the medical technology company’s stock valued at $1,538,302,000 after buying an additional 666,557 shares during the last quarter. Finally, Norges Bank purchased a new stake in Medtronic during the 2nd quarter valued at $1,432,698,000. 82.06% of the stock is currently owned by institutional investors.

Medtronic Stock Down 0.5%

Shares of Medtronic stock opened at $96.05 on Tuesday. Medtronic PLC has a 1 year low of $79.29 and a 1 year high of $106.33. The firm has a market cap of $123.13 billion, a price-to-earnings ratio of 25.89, a PEG ratio of 2.54 and a beta of 0.71. The company has a 50-day moving average of $97.54 and a 200 day moving average of $93.86. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business had revenue of $8.96 billion for the quarter, compared to analysts’ expectations of $8.86 billion. During the same quarter in the prior year, the company earned $1.26 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s payout ratio is presently 76.55%.

Analyst Ratings Changes

A number of research firms have issued reports on MDT. Daiwa Capital Markets boosted their price objective on shares of Medtronic from $104.00 to $117.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Jefferies Financial Group restated a “hold” rating and set a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. Leerink Partners set a $120.00 price target on Medtronic and gave the company an “outperform” rating in a research report on Wednesday, November 19th. Robert W. Baird set a $103.00 price objective on Medtronic in a research report on Tuesday, December 16th. Finally, Stifel Nicolaus boosted their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $109.94.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).